Aligos Therapeutics, Inc.
ALGSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Aligos Therapeutics, Inc. focuses on Biotechnology services and products. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. At a $29.8M market cap, Aligos Therapeutics, Inc. ranks as a micro-cap company within healthcare. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Market Cap
$29.8M
Beta
2.36
P/E (TTM)
—
P/E (Fwd)
-0.91
EPS (TTM)
$-7.41
EPS (Fwd)
$-5.25
ROE
-113.6%
ROA
-49.1%
Cash
$30.4M
Total Debt
$3.5M
Free CF
-$61.4M
52W Change
-51.1%
Annual Financials
Cash vs Debt
Where ALGS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ALGS finished 19.33% below its 150-day moving average ($6.00) and 24.73% below its 200-day moving average ($6.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALGS overbought or oversold?
At the October 20, 2026 close, ALGS's RSI(14) was 26.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $30.4M in cash comfortably exceeding the $3.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$61.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -113.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $13.9M (2022) to $2.2M (2025), a 84% decline worth watching.
Aligos Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, ALGS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ALGS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.